国产减肥药再获BD大单，GLP-1赛道未来走势如何？

澎湃新闻2025-07-31

一笔超20亿美元的对外授权交易（BD）让国产减肥药又火了一把。7月30日晚间，石药集团（1093.HK）公告称，与Madrigal Pharmaceuticals 达成一项独家全球许可协议，后者获得口服GLP-1受体激动剂SYH2086的全球开发、生产和商业化权利，但石药集团保留了该药在中国市场的权益。根据协议，此次交易的最高金额达到20.75亿美元，包含1.2亿美元首付款及高达19.55亿美元的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2555889392?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-31 17:59","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2555889392","market":"hk","top_or_hot":-1,"title":"国产减肥药再获BD大单，GLP-1赛道未来走势如何？","media":"澎湃新闻","content":"<div>\n<p>一笔超20亿美元的对外授权交易（BD）让国产减肥药又火了一把。7月30日晚间，石药集团（1093.HK）公告称，与Madrigal Pharmaceuticals 达成一项独家全球许可协议，后者获得口服GLP-1受体激动剂SYH2086的全球开发、生产和商业化权利，但石药集团保留了该药在中国市场的权益。根据协议，此次交易的最高金额达到20.75亿美元，包含1.2亿美元首付款及高达19.55亿美元的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118004194c5edb9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国产减肥药再获BD大单，GLP-1赛道未来走势如何？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国产减肥药再获BD大单，GLP-1赛道未来走势如何？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 17:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118004194c5edb9&s=b><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>一笔超20亿美元的对外授权交易（BD）让国产减肥药又火了一把。7月30日晚间，石药集团（1093.HK）公告称，与Madrigal Pharmaceuticals 达成一项独家全球许可协议，后者获得口服GLP-1受体激动剂SYH2086的全球开发、生产和商业化权利，但石药集团保留了该药在中国市场的权益。根据协议，此次交易的最高金额达到20.75亿美元，包含1.2亿美元首付款及高达19.55亿美元的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118004194c5edb9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0008369823.USD","symbol_name":"FSSA HONG KONG GROWTH \"I\" ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118004194c5edb9&s=b","article_id":"2555889392","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073118004194c5edb9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555889392","pubTimestamp":1753955963,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近几年，由于在糖尿病、肥胖等疾病领域的功效，GLP-1药物在全球走红。今年以来，国产创新药迎来BD出海热潮，也已经有多款国产GLP-1药物实现对外授权。当前，GLP-1单靶点药物已经出现司美格鲁肽、替尔泊肽两大单品，市场竞争激烈。GLP-1药物的热度有望持续，未来仍有BD潜力。随着终端需求的持续扩容，整个GLP-1产业链将持续步入景气度上行通道。尽管上述观点普遍乐观，但全球减肥药巨头“不及预期”的业绩还是给GLP-1赛道浇了一盆冷水。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","01801":"信达生物","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1191":"制药","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1515":"抗疫概念","01093":"石药集团","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","03933":"联邦制药","03692":"翰森制药","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1583":"高瓴概念","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC"},"translate_title":"Domestic weight loss pills have won another big BD order. What is the future trend of the GLP-1 track?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"03933":0.9,"01801":0.9,"03692":0.64},"content_text":"一笔超20亿美元的对外授权交易（BD）让国产减肥药又火了一把。7月30日晚间，石药集团（1093.HK）公告称，与Madrigal Pharmaceuticals 达成一项独家全球许可协议，后者获得口服GLP-1受体激动剂SYH2086的全球开发、生产和商业化权利，但石药集团保留了该药在中国市场的权益。根据协议，此次交易的最高金额达到20.75亿美元，包含1.2亿美元首付款及高达19.55亿美元的潜在里程碑款项，并基于产品净销售额支付最高双位数的分成比例。今年5月底，石药集团曾预告称，集团目前正与若干独立第三方就三项潜在交易进行磋商，单笔交易的最高金额或超50亿美元。从金额来看，此次交易不属于此前预告的三笔交易范畴。7月31日，石药集团最高涨近6%，午后转跌，最高跌超6%，截至收盘跌1.78%，报9.92港元/股，市值1143亿港元。近几年，由于在糖尿病、肥胖等疾病领域的功效，GLP-1药物在全球走红。今年以来，国产创新药迎来BD出海热潮，也已经有多款国产GLP-1药物实现对外授权。6月2日，翰森制药（3692.HK）宣布授予Regeneron公司GLP-1/GIP双受体激动剂HS-20094海外独占许可。根据协议，翰森制药将获得8000万美元首付款，并有资格根据该产品开发、注册审批和商业化进展收取最高19.3亿美元里程碑付款，以及未来潜在产品销售的双位数百分比特许权使用费。更早之前的3月，联邦制药（3933.HK）与诺和诺德就GLP-1/GIP/GCG受体激动剂UBT251达成协议，诺和诺德支付2亿美元预付款、18亿美元里程碑金额，以及一定比例的销售分成，最高总金额超20亿美元。当前，GLP-1单靶点药物已经出现司美格鲁肽、替尔泊肽两大单品，市场竞争激烈。可以看到，在GLP-1药物的交易中，交易标的通常有一定的差异化，如翰森制药和联邦制药对外授权的产品均属于多靶点GLP-1药物，在降糖、减重等方面或有更强大的效果。此次石药集团对外授权产品的亮点在于口服剂型，用药更具便利性。石药集团在公告中称，临床前数据显示， SYH2086具有优异的体外激动活性和体内降糖、减重效果，并在不同动物种属上具有宽剂量范围线性化的药物动力学(PK)行为，且无明显安全性风险。GLP-1药物的热度有望持续，未来仍有BD潜力。此前据证券时报报道，世界卫生组织（WHO）正在制定基于GLP-1疗法的成人肥胖症治疗新指南，计划于2025年9月正式发布。东吴证券研报指出，新指南有望进一步推动GLP-1类药物销售，未来减重药物发展方向分为Amylin（胰淀素）联用GLP-1、口服、减脂增肌三大赛道。华鑫证券此前研报指出，众生药业GLP-1双靶点药物RAY1225三期临床推进迅速。该产品为双周制剂，其24周用药治疗数据， 6mg和9mg体重较基线变化百分比≥5%和≥10%的减重达标率数值上均高于替尔泊肽，存在出海潜力。除了将管线授权出去，国产减肥药也在逐步实现商业化，如6月27日，信达生物（1801.HK）宣布其GCG/GLP-1双受体激动剂玛仕度肽注射液在国内获批，用于成人肥胖或超重患者的长期体重控制。光大证券研报认为，销售能力将成为考量企业未来竞争优势的重大要素，同时具备领先研发进度和强大销售执行力的企业将占据商业化竞争的优势地位。随着终端需求的持续扩容，整个GLP-1产业链将持续步入景气度上行通道。尽管上述观点普遍乐观，但全球减肥药巨头“不及预期”的业绩还是给GLP-1赛道浇了一盆冷水。7月29日，诺和诺德第二次下调业绩指引，预计销售增长为8%至14%，营业利润增长为10%至16%。公司称，下调主要是由于对2025年下半年增长的预期降低，涉及司美格鲁肽减重和降糖两大版本在美国市场的增长预期下调，以及减重版司美格鲁肽在部分市场的渗透率低于预期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555889392","isCrawlerRequest":true}